Skip to content
To the full analysis

City Therapeutics Stock: Balance Sheet and Debt

CTY
$18.35Closing price of 19 Nov 2026MEQIRI Score 58 out of 100

City Therapeutics has a debt to equity ratio of 0.59 and an interest coverage of over 100x. On paper, City Therapeutics would need 3 years of free cash flow like 2019 to pay off net debt of $5.95B.

Daily figure as of 20 Nov 2026

Debt / Equity
0.59
Interest coverage
> 100x
Current ratio
0.73
Cash & equivalents
$2M
Total assets
$21B
Equity ratio
48.2%
Goodwill
$9.36B
Plus intangible assets of $468M
Net debt
$5.95B

Balance Sheet Over Time

In all 10 fiscal years since 2010 debt exceeded cash. Interest coverage rose from 4.5x in 2014 to over 100x.

Total Assets and Equity Ratio

How large the balance sheet of City Therapeutics Inc. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2005no datanot reported separatelynot reported separatelyno data$7.7B
2006$14.85Bnot reported separatelynot reported separately11.6%$7.29B
2007$700Mnot reported separatelynot reported separately139.6%$7.59B
2008$307Mnot reported separatelynot reported separately256.0%$7.61B
2009$1.17Bnot reported separatelynot reported separately26.8%$7.94B
2010$221Mnot reported separatelynot reported separately−376.0%$7.21B
2011$17.39B$14.55B$9.45B56.9%$8.32B
2012$16.71B$13.75B$9.37B59.7%$7.62B
2013$16.01B$10.36B$9.35B60.0%$7.54B
2014$22.46B$12.39B$9.35B40.9%$7.37B
2015$21.47B$11.79B$9.35B41.5%$7.24B
2016$21.15B$11.23B$9.35B41.1%$7.26B
2017$20.87B$10.72B$9.36B44.7%$7.28B
2018$20.58B$10.25B$9.36B47.9%$5.95B
2019$21B$9.83B$9.36B48.2%$5.95B

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt.

Equity and Debt

What the Company Owns and Owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2005$32M$2.34B$7.73B3.31
2006$316M$1.73B$7.61B4.4
2007$44M$977M$7.63B7.81
2008$41M$786M$7.65B9.74
2009$17M$312M$7.96B25.5
2010$5M−$831M$7.21B−8.68
2011$3M$9.89B$8.33B0.84
2012$8M$9.97B$7.63B0.76
2013$14M$9.61B$7.56B0.79
2014$6M$9.18B$7.38B0.8
2015$3M$8.91B$7.24B0.81
2016$5M$8.69B$7.26B0.84
2017$1M$9.34B$7.28B0.78
2018$5M$9.87B$5.96B0.6
2019$2M$10.12B$5.95B0.59

Debt of Industry Peers

City Therapeutics's debt to equity is higher than that of 179 of 221 other stocks in the Biotechnology industry.

StockDebt to equityEquity ratio
SpyGlass Pharmano datano data
Vor Biopharmano datano data
Structure Therapeutics0.0095.7%
Seaport Therapeuticsno datano data
City Therapeutics0.5948.2%
Solid Biosciences0.1277.4%
Inventivano datano data
MoonLake Immunotherapeutics0.2571.7%
Silence Therapeutics0.0047.4%

Figures from the latest fiscal year. The eight peers closest in market value, largest first.

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Neutral since 7 Nov 2026
  • Price: closing price of 19 Nov 2026
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2019. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.